otilimab

Home
Ligands
otilimab

GtoPdb Ligand ID: 11132

Synonyms: GSK-3196165 | GSK3196165 | MOR-103 | MOR103

Comment: Otilimab (MOR103, GSK3196165) is a clinical stage fully human IgG1λ antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2). It is being investigated as a therapeutic for inflammatory diseases. MOR103 was developed using MorphoSys' HuCAL® technology, and has been fully out-licensed otilimab to GSK. MOR103 is claimed as MOR-04357 in patent WO2006122797A2 (by BLAST peptide sequence matching) [5].

References
1. Behrens F, Tak PP, Østergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A et al.. (2015) MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis, 74 (6): 1058-64. [PMID:24534756]
2. Constantinescu CS, Asher A, Fryze W, Kozubski W, Wagner F, Aram J, Tanasescu R, Korolkiewicz RP, Dirnberger-Hertweck M, Steidl S et al.. (2015) Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm, 2 (4): e117. [PMID:26185773]
3. Deiß A, Brecht I, Haarmann A, Buttmann M. (2013) Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev Neurother, 13 (3): 313-35. [PMID:23448220]
4. Hamilton JA. (2015) GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol, 11 (4): 457-65. [PMID:25748625]
5. Steidl S, Thomassen-Wolf E. (2006) Anti-gm-csf antibodies and uses therefor. Patent number: WO2006122797A2. Assignee: Morphosys Ag. Priority date: 18/05/2005. Publication date: 23/11/2006.

References

1. Behrens F, Tak PP, Østergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A et al.. (2015)
MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.
Ann Rheum Dis, 74 (6): 1058-64. [PMID:24534756]

2. Constantinescu CS, Asher A, Fryze W, Kozubski W, Wagner F, Aram J, Tanasescu R, Korolkiewicz RP, Dirnberger-Hertweck M, Steidl S et al.. (2015)
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.
Neurol Neuroimmunol Neuroinflamm, 2 (4): e117. [PMID:26185773]

3. Deiß A, Brecht I, Haarmann A, Buttmann M. (2013)
Treating multiple sclerosis with monoclonal antibodies: a 2013 update.
Expert Rev Neurother, 13 (3): 313-35. [PMID:23448220]

4. Hamilton JA. (2015)
GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential.
Expert Rev Clin Immunol, 11 (4): 457-65. [PMID:25748625]

5. Steidl S, Thomassen-Wolf E. (2006)
Anti-gm-csf antibodies and uses therefor.
Patent number: WO2006122797A2. Assignee: Morphosys Ag. Priority date: 18/05/2005. Publication date: 23/11/2006.